PTGX Projected Dividend Yield
Protagonist Therapeutics Inc ( NASDAQ : PTGX )Protagonist Therapeutics, Inc. is a biopharmaceutical company. Co. uses its peptide-based chemical entities rusfertide and JNJ-2113 in different stages of development, all derived from its proprietary discovery technology platform. Co.'s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its lead clinical asset, rusfertide (PTG-300), is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. 21 YEAR PERFORMANCE RESULTS |
PTGX Dividend History Detail PTGX Dividend News PTGX Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |